Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
Background: About a third of patients with inflammatory bowel disease do not respond to anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the current data on the two main strategies when facing primary non-response to an anti-TNF agent in inflammatory bowel disease...
Main Authors: | Javier P. Gisbert, María Chaparro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/22/5318 |
Similar Items
-
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Rayer Cassandra, et al.
Published: (2022-12-01) -
Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01) -
Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu
by: María José García, et al.
Published: (2021-09-01) -
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
by: Tina Deyhim, et al.
Published: (2023-11-01) -
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study
by: Francesca Ferretti, et al.
Published: (2022-08-01)